Whole-Exome sequencing identifies a Type 2 Diabetes candidate mutation in *PTPRF*

Running title: *PTPRF* and Type 2 Diabetes

Erik J.M. Toonen¹, Michael Kwint², Alexander Hoischen² and Cees J. Tack³

Affiliations

¹R&D department, Hycult Biotech b.v., Fronstraat 2a, 5405 PB, Uden, The Netherlands

²Departments of Human Genetics and ³Internal Medicine, Radboud University Medical Center (Radboudumc), Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.

Corresponding Author

Cees J. Tack (Cees.Tack@radboudumc.nl), Department of Internal Medicine, Radboud University Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel: +31 24 3618819

Funding

E.T. was supported by an EFSD/Novo Nordisk research grant provided by the European Foundation for the Study of Diabetes (EFSD) and by a grant of the Else-Kröner-Fresenius-Stiftung.

25 **Author contributions**

26

27 ET: designed the study, performed the experiments, analyzed and interpreted the results,
28 wrote the manuscript. MK: performed the experiments, analyzed and interpreted the
29 results. AH: designed the study, analyzed and interpreted the results, revised the
30 manuscript. CT: designed the study, analyzed and interpreted the results, revised the
31 manuscript.

32

33 **Word count:** 3404 (excl. references)

Abstract

Objectives: Identification of genetic factors involved in Type 2 diabetes mellitus (T2DM) has been challenging. While genome-wide association studies (GWAS) have identified over 60 loci associated with T2DM, these variants only explain a small proportion of the total heritability of the disease. Whole-exome sequencing has become a powerful approach to identify genetic variants that are not captured by GWAS. We applied exome sequencing to identify causal genetic variants in a family with a 2-generation history of T2DM characterized by substantial insulin resistance, hypertension and isolated hypertriglyceridemia. **Methods:** Exome sequencing was performed on genomic DNA of two affected family members. Twenty-four identified variants that were present in both family members were further tested for segregation in all other family members by Sanger sequencing. **Results:** Three rare missense variants, located in the genes *PTPRF*, *FUCA1* and *FBXO30*, were present in all affected family members but also in one unaffected family member. Protein-protein interaction analysis showed that *PTPRF* strongly interacts with several members of the insulin signaling pathway.

Conclusions: Our results suggest that the variant in the *PTPRF* gene might be causal for an unusual T2DM subtype that is characterized by a severe insulin resistance and isolated hypertriglyceridemia.

Keywords: Whole-exome sequencing, Insulin resistance, Genetics of Type 2 Diabetes, Hypertriglyceridemia, Rare genetic variants.

Introduction

Type 2 diabetes mellitus (T2DM) is a complex multifactorial trait where both environmental and genetic factors contribute to the pathogenesis of the disease. Based on twin and segregation studies, the heritability of type 2 diabetes has been estimated to be between 36 and 83 percent [1, 2]. Large-scale genome-wide association studies (GWAS) have contributed towards understanding the inherited basis of diabetes. In the past few years, GWA studies have identified over numerous loci associated with T2DM [3-7]. However, these identified genetic variants account for less than 6 percent of the heritability estimated from family studies [8]. Because these common variants explain only a small fraction of the estimated heritability, it has been hypothesized that rare genetic variants with large effect sizes contribute to the genetic predisposition of T2DM. Traditional genotyping platforms used in GWAS are primarily designed to capture common genetic polymorphisms but offer poor coverage of rare genetic variants, hence rare disease variants with large effect sizes are easily missed [9]. Approaches other than GWAS are necessary to identify the remaining genetic variants underlying the pathogenesis of type 2 diabetes in order to improve diagnosis and treatment strategies.

Recently, whole-exome sequencing has become a powerful strategy to identify low-frequency and rare variants not captured by GWAS [10]. Sequencing of all genes (exome) is an approach relying on the hypothesis that functional disease-associated variation resides in the coding regions. Whole-exome sequencing has proven to be valuable for identifying mutations responsible for monogenic diseases [11] and emerging reports show that exome sequencing can also be applied to uncover variation associated with complex human traits [12, 13]. While T2DM consists of both decreased insulin

80 secretion and reduced insulin action (insulin resistance), most genetic defects identified
81 so far relate to insulin secretion and genetic factors in obesity-induced insulin resistance
82 seem to be underreported [14].

83 In the present study, we apply exome sequencing to identify genetic variants that
84 may have a role in disease susceptibility in a family with a 2-generation history of type 2
85 diabetes, with an unusual phenotype characterized by pronounced insulin resistance and
86 hypertriglyceridemia.

Methods

Family members

We recruited a family with a 2-generation family history of T2DM . The index cases were under chronic diabetes care in the hospital. Due to privacy reasons, the pedigree is not published, please contact the corresponding author for further information.

Case presentations

The index case presented with diabetes in his late thirties with a six months period of weight loss (14 kg) and balanitis. Body weight at presentation 80.5 kg, height 1.73 (BMI 26.7 kg/m²), blood pressure 150/100. Laboratory analysis revealed HbA_{1c} 12.5%, ALAT slightly elevated, urine ketones negative. Patient started oral combination therapy (SU and metformin), with temporary improvement, but secondary glycemic failure after approximately 2 years. Before start of insulin his laboratory parameters were: HbA_{1c}: 9.2%, total cholesterol 5.3, Triglycerides 4.9, HDL-cholesterol 0.70, LDL 2.51 mmol/L (all fasting and without statin), fasting insulin level: 30 mU/L, C-peptide: 1.54 nmol/L, ASAT 21, ALAT 39, urine albumin 20 mg/L. Patient was started on insulin, eventually administered by pump, up to 140 U/day (body weight increased to 94 kg, BMI 31.4 kg/m²). His triglyceride levels remained elevated. See Table 1 for details.

A relative was diagnosed with diabetes in his sixties during routine medical examination. He was overweight (weight 87.5 kg, height 1.78, BMI 27,6 kg/m²) and had hypertension, micro-albuminuria, hypertriglyceridemia and low HDL-cholesterol. He was eventually treated with insulin, up to 160 U/day. He always had elevated triglyceride levels.

The clinical phenotype of affected family members was characterized by substantial insulin resistance, hypertension and hypertriglyceridemia without hypercholesterolemia. Data from one affected relative were retrieved from another hospital. Data from an unaffected relatives were obtained during a short hospital visit, data from one unaffected relative were obtained through his GP and by telephone. In family members with diabetes, detailed information regarding onset of diabetes, complications and treatment was obtained. In unaffected family members, BMI and blood pressure was measured and fasting glucose, and HbA1c (to exclude diabetes) and lipids levels were measured. Results are depicted in Table 1. There was no information suggesting consanguineous marriage in the family.

Non-related diabetes subjects

To validate our initial results obtained from the analysis of the family members, we selected 24 non-related subjects who matched the characteristics of the affected family members (insulin > 1U/kg or >100 U/day; TG > 1,5 mmol/l; BMI < 35 kg m²). Subjects were selected from the Diabetes Pearl patient cohort. This cohort is a large, well-characterized observational cohort of type 2 diabetes patients. The Diabetes Pearl cohort is a collaborative biobank initiative from the Dutch University Medical Centers (www.parelsnoer.org) [15]. DNA samples were retrieved from the Biobank after approval of the ethics committee.

Whole-Exome sequencing

Exome sequencing was essentially performed as described previously [16, 17]. In brief, exome enrichment was performed using the SureSelect Human Exon 50-Mb Kit (Agilent,

Santa Clara, CA, USA), covering approximately 22,000 genes, followed by SOLiD4 sequencing (Life Technologies, Carlsbad, CA, USA). Reads were mapped to the hg19 reference genome using SOLiD LifeScope software version 2.1. All nonsynonymous variants shared in both affected individuals and absent or with very low frequency (0.1%) in dbSNP, were further investigated in healthy and affected family members.

Sanger Sequencing

Nonsynonymous variants identified by exome sequencing were tested in healthy and affected family members for co-segregation by traditional Sanger sequencing. Forward and reverse PCR primers for each exon in which the variant was located were selected in an intronic sequence 50 bp away from the intron/exon boundaries. Unique primers were designed using the Primer3 software. PCR products were verified on 2% agarose gel, purified using ExoSAP-IT (Affymetrix, Santa Clara, CA, USA) and analyzed on ABI3730 genetic analyzers (Life Technologies, Carlsbad, CA, USA).

Ion torrent library preparation and sequencing

All 32 coding exons of the *PTPRF* gene were analyzed in 24 unrelated diabetes patients who matched the clinical characteristics of the affected family members. The screening of 24 patients for variants in the *PTPRT* gene was carried out by using an Amplicon-based deep-sequencing approach on the Ion PGM sequencer (Life Technologies, Carlsbad, CA, USA). PCR amplicons were generated per sample using standard PCR protocols. Primer sequences are available upon request. PCR products per sample were pooled, and subsequently sheared to 200-bp fragments by the use of Covaris E210 (Covaris Inc.). Library preparation was performed using the Ion Xpress™ Plus Fragment Library Kit in

combination with the Ion Xpress Barcode adapters 1-96 kit. Emulsion PCR and enrichment were carried out on the Ion OneTouch System using the Ion PGM TemplateOT2 200 Kit as described by the manufacturer. Sequencing was performed using the 200bp kitv2, with Ion Sphere particles loaded to an Ion318™ chip (Life Technologies Carlsbad, CA, USA). Raw sequencing reads were mapped to the hg19 genome using the Torrent Server with the use of the Torrent suite software. FASTQ files were subsequently analyzed and visualized in SeqNext (JSI Medical systems).

Protein-protein interaction analysis

Protein-protein interactions (PPI) were identified using the STRING database (STRING v9.1; <http://string-db.org/>) [18]. STRING builds functional protein association networks based on compiled available experimental evidence. A confidence score is assigned to each identified protein–protein association and this score will increase when an association is supported by several types of evidence. In this study, only PPI are shown that yielded a high confidence score (≥ 0.7).

Ethics

All family members were informed about the goal of the study and consented to participation.

Results

Characteristics of family members

Characteristics of affected and unaffected family members are shown in Table 1.

Whole-Exome sequencing identifies variants within the PTPRF and ASXL1 genes

Exome sequencing was performed on genomic DNA of two family members with an average 46- and 81-fold coverage leading to 85.2% and 87.9% of the exome with at least 10-fold coverage, respectively. We identified 38,067 and 39,293 genetic variants per proband in the two family members, respectively. Variants were annotated by a bioinformatics pipeline as previously described [16]. In addition, the variant had to be present in at least 20-80% of all reads suggestive of heterozygous changes in a dominant model of disease. Subsequently, genetic variants were prioritized based on predicted amino acid consequences and overlap with common genetic variants (listed in dbSNP version 135 and/or present in an in-house database containing >10,000 analyzed exomes of predominantly European ancestry). All filter steps are shown in Supplementary Table 1.

We identified 21 unique non-synonymous variants present in both affected family members that were present in genes with known expression in adipose tissue (Table 2, Supplementary Table 1). All 21 variants were tested for segregation in all other family members by Sanger sequencing (Table 3). Two rare missense variants were present in all affected family members but also in one unaffected family member. Variants c.3614A>G (rs200885607; p.(N11965S); located in the gene *Protein tyrosine phosphatase, receptor type F* (PTPRF; NM_002840)) and c.904C>T p.(R302C); located in the gene *ASXL*

transcriptional regulator 1 (ASXL1; NM_015338)) were also present in the non-affected family member II/4 (Table 3). The c.3614A>G variant within *PTPRF* was detected once in the in genome-wide sequence data from the 1000 Genomes Project which include the genomes of 1088 people (or 2176 chromosomes) [19]. The variant was present at very low frequency in public exome datasets, e.g. ExAc browser frequency 12/121398 alleles, i.e. allele frequency of 9.885×10^{-5} ; with 7/66730 alleles in Non-Finish Europeans (0.0001049 allele frequency) (<http://exac.broadinstitute.org/> [August 2019]) and also with very low allele frequency in the in-house exome database (0.00045 in > 8000 exomes). The *ASXL1* variant was never observed in ExAc nor in the in-house database. *In silico* predictions for both variants can be seen in Supplementary Table 2.

PTPRF strongly interacts with proteins involved in insulin signaling.

To investigate/identify in which biological processes and pathways the genes *PTPRF* and *ASXL1* are involved, we used the STRING database to search for predicted and published protein-protein interactions. Analysis showed that *PTPRF* strongly interacts with several members of the insulin signaling pathway. High confidence scores were assigned to the interactions between *PTPRF* and *Insulin receptor (INSR)* and *Insulin receptor substrate 1 and 2 (IRS1 and 2)* (Table 4, Figure 1A). Indeed, *PTPRF* was demonstrated to be expressed in several insulin sensitive tissues where it interacts with the insulin receptor and dephosphorylates its tyrosine-kinase domain, thereby inhibiting its activation and downstream signaling [20]. These results point out to an important role for *PTPRF* in insulin signaling. Protein-protein interaction analysis also revealed that *ASXL1* did not interact with proteins involved in insulin signaling, glucose metabolism or other

biological processes that are likely to play a role in the pathogenesis of type 2 diabetes
(Table 4 and Figure 1B).

Investigation of the PTPRF gene in an additional cohort of T2DM patients

The results described above clearly pointed out to *PTPRF* as a strong candidate gene for this T2DM phenotype. To validate our results, we investigated the *PTPRF* gene for the possible presence of genetic variants in an additional cohort of 24 unrelated T2DM patients. These patients were selected based upon disease characteristics that matched the characteristics of the affected family members (insulin > 1U/kg or 100 U/day; TG > 1,5 mmol/l; BMI < 35 kg m²). All coding exons of the *PTPRF* gene were sequenced in these 24 patients by the use of Ion torrent sequencing. The c.3614A>G variant was not present in these 24 patients. Also no additional rare variants were detected in this cohort.

Discussion

In the present study, we applied whole-exome sequencing to identify genetic variants possibly involved in disease susceptibility in a family with T2DM, characterized by substantial insulin resistance, hypertension and hypertriglyceridemia in the absence of hypercholesterolemia. We identified the rare variant c.3614A>G, located within the *PTPRF* gene, as a novel candidate susceptibility variant. Sequencing of all coding exons of the *PTPRF* gene in a cohort of 24 non-related T2DM patients did not reveal any additional variants. Our results suggest that the c.3614A>G variant might play a role in an unusual T2DM subtype that is characterized by a severe insulin resistance and “isolated” hypertriglyceridemia. Identification of genetic variants responsible for specific forms of

diabetes provide new insights regarding underlying disease aetiology. These new insights may help to improve diagnosis and to optimize treatment strategies in these specific T2DM subtypes.

The c.3614A>G variant was detected in all affected family members but also in one unaffected family member. Although this family member was not diagnosed with type 2 diabetes, his triglyceride levels were elevated. All family members with diabetes had episodes with grossly elevated TG levels (>10 mmol/L), fairly independent of age, but occasionally also showed less elevated TG levels. TG level was, however, always above the normal range. TG level in the genetically affected family member without diabetes was moderately elevated in one single blood sample. Perhaps this person had a combination of relative active lifestyle and excellent beta-cell function, resulting in absence of diabetes. Additionally, T2DM is a multifactorial disease in which both genetic as environmental factors play a role. Another reason why this individual carries the c.3614A>G variant but was not diagnosed with T2DM might be reduced penetrance. As often seen for multifactorial diseases with a heritable component, the c.3614A>G variant may have reduced penetrance, meaning that some individuals fail to express the trait, even though they carry the allele. The degree of penetrance is difficult to determine and is often age related. Given that the onset of symptoms in T2DM are age related and affected by both genetic as well as environmental factors such as nutrition, it is possible that this individual will develop the disease in the near future, although he is currently older than the age at which the diabetes was diagnosed in his brothers.

Although we cannot exclude the variant located in *ASXL1* as a candidate, the evidence for *PTPRF* as a candidate gene for T2DM is more convincing. Our finding that a genetic variant within *PTPRF* may be involved in the pathogenesis of type 2 diabetes is

supported by earlier studies. Miscio and co-workers investigated whether common polymorphisms within the *PTPRF* gene were associated with insulin resistance. They identified a single nucleotide polymorphism (SNP) within the promoter region (-127T>A; rs3001722) in which the A allele (minor allele) was associated with lower body mass index (BMI), waist circumference and mean blood pressure in a cohort of 589 unrelated non-diabetic subjects. In addition, the A allele was associated with lower triglycerides, glucose and insulin levels during an oral glucose tolerance test (oGTT) in an independent cohort of 307 unrelated non-diabetic individuals [21]. Menzaghi and co-workers report an association between the SNP 2518A>G (rs2782641), located within intron 3, and coronary artery disease (CAD) in a T2DM patient cohort including 592 individuals [22]. To our knowledge, the c.3614A>G variant has not been reported in literature in relation to T2DM. These studies, together with our results, suggest that genetic variants within *PTPRF* are contributing to insulin resistance and T2DM in at least a subpopulation of patients.

PTPRF is a receptor-type transmembrane protein tyrosine phosphatase (PTPase) that is expressed in several insulin target tissues [23]. It physically interacts with the insulin receptor and dephosphorylates its tyrosine-kinase domain thereby inhibiting insulin signaling [24]. Transgenic mice overexpressing *PTPRF* are insulin resistant [25] and, conversely, *PTPRF* knock-out mice are characterized by increased insulin sensitivity [26]. *PTPRF* is therefore a potential candidate gene for insulin resistance. Regarding *ASXL1*, no studies were reported showing evidence that *ASXL1* is involved in the pathogenesis of T2DM.

Most studies investigating the genetic background of T2DM are focusing on identifying common variants that are associated with the disease [8, 27-29]. However,

most studies have not been particularly successful in discovering new disease genes. As a consequence, the rare variant hypothesis [30, 31], which states that rare variants with large effects are the primary drivers of common diseases, has received renewed attention. Studies investigating Mendelian diseases have demonstrated that a family-based approach is a good method to detect these rare variants with relatively high impact on disease [32]. Rare variants are not present in the general population at any reasonable frequency and an advantage of a family-based study is that more observations of a rare variant can be made in large families. However, type 2 diabetes is a late-onset disease and recruiting such families is challenging. We identified this family because of the unusual phenotype of the index patient, and noted the familial existence of the combination of severe insulin resistance and “isolated” hypertriglyceridemia: hypertriglyceridemia in the absence of hypercholesterolemia. As expected, hypertriglyceridemia was associated with decreased HDL-cholesterol levels. In this study, we used the family-based approach combined with whole-exome sequencing to detect variants that may have a role in susceptibility for the disease in this family. We were able to identify a rare variant located in a strong T2DM candidate gene, which suggests that the family-based approach combined with whole-exome sequencing may be a useful strategy to investigate the genetic background of type 2 diabetes.

While our findings suggest that the c.3614A>G variant in *PTPRF* may underly the phenotype of the this family, we were unable to identify a second family within our facility that resembles the disease characteristics observed in this first family, despite sharing this as a candidate gene via genematcher.com [33, 34]. In addition, no variants in *PTPRF* were identified in a patient cohort of 24 unrelated T2DM patients who phenotypically matched the characteristics of the affected family members. Our study

lacks confirmation through functional studies, which should be included in future investigations. We realize that it is possible that the identified variant is a false positive result. However, we would like to stress that the variant in *PTPRF* was identified using an unbiased, non-candidate gene driven, whole exome-wide approach and that the gene is known to be involved in insulin signaling and associated with metabolic disturbances. To our opinion, this suggests that *PTPRF* is a potential candidate gene that, at least, should be added to the discussion regarding genetic variants underlying T2DM. In that light, it might be best to see this report as a case report providing researchers and clinicians the opportunity to respond and set up collaborations in order to identify additional cases/families.

In summary, we applied whole-exome sequencing to identify genetic variants possibly involved in T2DM disease susceptibility in a family with highly aggregated type 2 diabetes. Our results suggest that the c.3614A>G variant in the *PTPRF* gene play a role in an unusual T2DM subtype that is characterized by a severe insulin resistance and isolated hypertriglyceridemia. These results indicate that combining the family-based approach with whole-exome sequencing may be a useful strategy to further unravel the genetic background of type 2 diabetes. The genetic variant identified within this study represents a promising candidate for stratification of T2DM patients regarding mild or severe insulin resistance. Follow-up studies are needed to confirm that the identified variant in the *PTPRF* gene is indeed responsible for severe insulin resistance and isolated hypertriglyceridemia and to further unravel the precise working mechanism responsible for this unusual T2DM phenotype. If several independent studies are able to confirm our initial results, this genetic variant may have additional value for diagnosis and to optimize

348 treatment strategies in patients with this unusual T2DM subtype that is characterized by
349 severe insulin resistance and isolated hypertriglyceridemia.

List of abbreviations

ALAT: alanine aminotransferase, ASAT: Aspartaat-aminotransferase, BMI: body mass index, CAD: coronary artery disease, GP: general practitioner, GWAS: genome-wide association study, HbA1c: hemoglobin A1c, HDL: high-density lipoprotein, LDL: low-density lipoprotein, oGTT: oral glucose tolerance test, PCR: polymerase chain reaction, PPI: protein-protein interaction, SNP: single nucleotide polymorphism, SU: Sulphonylureas, T2DM: Type 2 diabetes mellitus, TG: triglycerides

Acknowledgements

The authors would like to thank Lisenka E.L.M. Vissers, Petra de Vries, Marloes Steehouwer and Christian Gilissen for their help and advice during this study. The authors are very grateful to the patients and family members who made it possible to perform this study.

Funding

E.T. was supported by an EFSD/Novo Nordisk research grant provided by the European Foundation for the Study of Diabetes (EFSD) and by a grant of the Else-Kröner-Fresenius-Stiftung.

Conflicts of interests

None declared

Declarations

Ethics approval and consent to participate

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. All family members were informed about the goal of the study and consented to participation. Study was approved by the The local Medical Ethical Committee, Commissie Mensgebonden Onderzoek (CMO) regio Arnhem-Nijmegen.

Consent for publication

Consent to publish was obtained from all individuals.

Availability of data and material

Please contact author for data requests

References

1. Kaprio, J., et al., *Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland*. Diabetologia, 1992. **35**(11): p. 1060-7.
2. *Diabetes mellitus in twins: a cooperative study in Japan*. Committee on Diabetic Twins, Japan Diabetes Society. Diabetes Res Clin Pract, 1988. **5**(4): p. 271-80.
3. O'Rahilly, S., I. Barroso, and N.J. Wareham, *Genetic factors in type 2 diabetes: the end of the beginning?* Science, 2005. **307**(5708): p. 370-3.
4. Witka, B.Z., et al., *Type 2 Diabetes-Associated Genetic Polymorphisms as Potential Disease Predictors*. Diabetes Metab Syndr Obes, 2019. **12**: p. 2689-2706.
5. Fuchsberger, C., et al., *The genetic architecture of type 2 diabetes*. Nature, 2016. **536**(7614): p. 41-47.
6. Moltke, I., et al., *A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes*. Nature, 2014. **512**(7513): p. 190-3.
7. Flannick, J., et al., *Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls*. Nature, 2019. **570**(7759): p. 71-76.
8. Morris, A.P., et al., *Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes*. Nat Genet, 2012. **44**(9): p. 981-90.
9. Lohmueller, K.E., et al., *Whole-exome sequencing of 2,000 Danish individuals and the role of rare coding variants in type 2 diabetes*. Am J Hum Genet, 2013. **93**(6): p. 1072-86.

- 421 10. Holm, H., et al., *A rare variant in MYH6 is associated with high risk of sick sinus*
422 *syndrome*. Nat Genet, 2011. **43**(4): p. 316-20.
- 423 11. Ng, S.B., et al., *Exome sequencing identifies the cause of a mendelian disorder*.
424 Nat Genet, 2010. **42**(1): p. 30-5.
- 425 12. Samocha, K.E., et al., *A framework for the interpretation of de novo mutation in*
426 *human disease*. Nat Genet, 2014.
- 427 13. Bernier, R., et al., *Disruptive CHD8 Mutations Define a Subtype of Autism Early*
428 *in Development*. Cell, 2014. **158**(2): p. 263-76.
- 429 14. Grarup, N., et al., *Genetic susceptibility to type 2 diabetes and obesity: from*
430 *genome-wide association studies to rare variants and beyond*. Diabetologia, 2014.
431 **57**(8): p. 1528-41.
- 432 15. Van't, R.E., et al., *The Diabetes Pearl: Diabetes biobanking in The Netherlands*.
433 BMC.Public Health, 2012. **12**: p. 949.
- 434 16. Hoischen, A., et al., *De novo mutations of SETBP1 cause Schinzel-Giedion*
435 *syndrome*. Nat Genet, 2010. **42**(6): p. 483-5.
- 436 17. van, d., V, et al., *STAT1 mutations in autosomal dominant chronic mucocutaneous*
437 *candidiasis*. N.Engl.J.Med., 2011. **365**(1): p. 54-61.
- 438 18. Franceschini, A., et al., *STRING v9.1: protein-protein interaction networks, with*
439 *increased coverage and integration*. Nucleic Acids Res, 2013. **41**(Database
440 issue): p. D808-15.
- 441 19. Genomes Project, C., et al., *A map of human genome variation from population-*
442 *scale sequencing*. Nature, 2010. **467**(7319): p. 1061-73.
- 443 20. Hashimoto, N., et al., *Insulin receptor protein-tyrosine phosphatases. Leukocyte*
444 *common antigen-related phosphatase rapidly deactivates the insulin receptor*

- 445 *kinase by preferential dephosphorylation of the receptor regulatory domain. J*
446 *Biol Chem*, 1992. **267**(20): p. 13811-4.
- 447 21. Miscio, G., et al., *The allelic variant of LAR gene promoter -127 bp T-->A is*
448 *associated with reduced risk of obesity and other features related to insulin*
449 *resistance. J Mol Med (Berl)*, 2004. **82**(7): p. 459-66.
- 450 22. Menzaghi, C., et al., *The protein tyrosine phosphatase receptor type f (PTPRF)*
451 *locus is associated with coronary artery disease in type 2 diabetes. J Intern Med*,
452 2008. **263**(6): p. 653-4.
- 453 23. Tsujikawa, K., et al., *Distinct functions of the two protein tyrosine phosphatase*
454 *domains of LAR (leukocyte common antigen-related) on tyrosine*
455 *dephosphorylation of insulin receptor. Mol Endocrinol*, 2001. **15**(2): p. 271-80.
- 456 24. Goldstein, B.J., et al., *Regulation of the insulin signalling pathway by cellular*
457 *protein-tyrosine phosphatases. Mol Cell Biochem*, 1998. **182**(1-2): p. 91-9.
- 458 25. Zabolotny, J.M., et al., *Overexpression of the LAR (leukocyte antigen-related)*
459 *protein-tyrosine phosphatase in muscle causes insulin resistance. Proc Natl Acad*
460 *Sci U S A*, 2001. **98**(9): p. 5187-92.
- 461 26. Ren, J.M., et al., *Transgenic mice deficient in the LAR protein-tyrosine*
462 *phosphatase exhibit profound defects in glucose homeostasis. Diabetes*, 1998.
463 **47**(3): p. 493-7.
- 464 27. Replication, D.I.G., et al., *Genome-wide trans-ancestry meta-analysis provides*
465 *insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet*,
466 2014. **46**(3): p. 234-44.

28. Albrechtsen, A., et al., *Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes*. Diabetologia, 2013. **56**(2): p. 298-310.
29. Manning, A.K., et al., *A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance*. Nat Genet, 2012. **44**(6): p. 659-69.
30. Bodmer, W. and C. Bonilla, *Common and rare variants in multifactorial susceptibility to common diseases*. Nat Genet, 2008. **40**(6): p. 695-701.
31. Pritchard, J.K. and N.J. Cox, *The allelic architecture of human disease genes: common disease-common variant...or not?* Hum Mol Genet, 2002. **11**(20): p. 2417-23.
32. Saad, M. and E.M. Wijsman, *Power of family-based association designs to detect rare variants in large pedigrees using imputed genotypes*. Genet Epidemiol, 2014. **38**(1): p. 1-9.
33. Sobreira, N., et al., *GeneMatcher: a matching tool for connecting investigators with an interest in the same gene*. Hum Mutat, 2015. **36**(10): p. 928-30.
34. Sobreira, N., et al., *New tools for Mendelian disease gene identification: PhenoDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene*. Hum Mutat, 2015. **36**(4): p. 425-31.

489 **Tabel 1.** Characteristics of family members

Family member	Phenotype									
	Diabetes	AGE of ONSET	HT	AGE	BMI (kg/m ²)	Insulin dose (U/kg)	Total Cholesterol (mmol/l)	Triglycerides (mmol/l)	HDL-cholesterol (mmol/l)	LDL-Cholesterol (mmol/l)
1	Yes	60s	Yes	80s†	27	1.9	4.4 - 4.7	3.6 – 4.7	0.6	2.2
2	No		Yes	Late 80s	35	N/A	4.9	2.5	0.8	3.0
3	Yes [#]	20s	Yes	Late 50s	19	1.0	3.7	4.4 (max 25)	0.8	1.0
4	Yes	Late 30s	Yes	Late 50s	31	1.6	5.3	4.9	0.7	2.5
5	No		No	50s†	?	N/A				
6	No		Yes	50s	27	N/A	4.8	1.9	1.1	2.9
7	Yes [#]	Late 30s	Yes	50s	27	0.9	4.5	2.9	0.9	2.2
8	No		No	Late 40s	30	N/A	5.1	3.4	0.9	2.7

490 [#]denoted as type 1 diabetes but no auto-immunity tested; HT: hypertension; BMI: Body Mass Index

491 †Died at indicated age

492 **Table 2.** Overview of the 21 unique nonsynonymous variants present in both affected family members.

Gene symbol	Gene ID	Chromosome	Reference	Mutation	Start position	End position	Abberation	Reference Amino Acid	Mutation Amino Acid	Conservation score
<i>PDLIM5</i>	NM_006457	chr4	C	T	95561564	95561564	substitution	R	*	1.933
<i>PARP6</i>	NM_020214	chr15	G	A	72553972	72553972	substitution	H	Y	9.711
<i>KTN1</i>	NM_004986	chr14	C	T	56094742	56094742	substitution	T	I	3.371
<i>NEXN</i>	NM_001172309	chr1	A	G	78399073	78399073	substitution	E	G	8.789
<i>PCNX</i>	NM_014982	chr14	C	T	71428992	71428992	substitution	P	S	6.163
<i>PTPRF</i>	NM_002840	chr1	A	G	44072041	44072041	substitution	N	S	-0.606
<i>NPR1</i>	NM_000906	chr1	T	C	153660586	153660586	substitution	L	P	1.801
<i>DCAF8</i>	NM_015726	chr1	T	G	160209533	160209533	substitution	Q	P	0.727
<i>C10orf128</i>	NM_001288742	chr10	G	A	50364232	50364232	substitution	S	L	-0.062
<i>PYROXD1</i>	NM_024854	chr12	A	G	21602560	21602560	substitution	K	E	5.191
<i>POLR2A</i>	NM_000937	chr17	A	G	7417024	7417024	substitution	Q	R	1.397
<i>CHD3</i>	NM_001005271	chr17	T	C	7810699	7810699	substitution	L	P	0.563
<i>PARD3B</i>	NM_152526	chr2	C	G	206480223	206480223	substitution	R	G	3.724
<i>LANCL1</i>	NM_001136574	chr2	A	C	211306083	211306083	substitution	F	L	2.365
<i>ASXL1</i>	NM_015338	chr20	C	T	31019407	31019407	substitution	R	C	4.337
<i>PRMT2</i>	NM_001242865	chr21	C	T	48071838	48071838	substitution	L	F	-0.331
<i>GOLIM4</i>	NM_014498	chr3	C	T	167728086	167728086	substitution	E	K	3.176
<i>GTPBP2</i>	NM_019096	chr6	C	A	43591700	43591700	substitution	E	D	0.073
<i>MATN2</i>	NM_002380	chr8	T	C	98991158	98991158	substitution	C	R	6.292
<i>PRUNE2</i>	NM_015225	chr9	G	A	79267561	79267561	substitution	R	W	1.445
<i>AKNA</i>	NM_030767	chr9	C	T	117139699	117139699	substitution	G	R	-0.126

493 *stop mutation; conservation score: PhyloP; measures acceleration (faster evolution than expected under neutral drift) as well as
494 conservation (slower than expected evolution). The absolute values of the scores represent $-\log$ p-values under a null hypothesis of neutral
495 evolution.

496 **Table 3.** Segregation of the 21 identified variants in all family members.

Gene symbol	Family member							
	1	2	3	4	5	6	7	8
	Affected	Not affected	Affected	Affected	Not affected	Not affected	Affected	Not affected
<i>NFR1</i>	AG	AA	AA	AG	AA	AG	AA	AA
<i>DCAF8</i>	TT	-	-	TT	-	-	-	-
<i>C10orf128</i>	GA	GG	GG	GA	GA	GG	GG	GG
<i>PYROXD1</i>	AG	AA	AG	AG	AA	AA	AA	AA
<i>POLR2A</i>	AG	AA	AA	AG	AA	AG	AA	AA
<i>CHD3</i>	TC	TT	TT	TC	TT	TC	TT	TT
<i>PAR3B</i>	CG	CC	CG	CG	CG	CG	CG	CC
<i>LANCL1</i>	AC	AA	AC	AC	AC	AC	AC	AA
<i>ASXL1</i>	CT	CC	CT	CT	CC	CT	CT	CC
<i>PRMT2</i>	CT	CC	CC	CT	CT	CC	CC	CT
<i>GOLIM4</i>	CT	CC	CT	CT	CT	CT	CT	CT
<i>GTPBP2</i>	CC	-	-	CC	-	-	-	-
<i>MATN2</i>	TC	TT	TC	TC	TC	TT	TT	TC
<i>PRUNE2</i>	GA	GG	GG	GA	GA	GA	GA	GA
<i>AKNA</i>	CT	CC	CC	CT	CT	CT	CT	CC
<i>PDLIM5</i>	CT	CC	CC	CT	CC	CC	CT	CT
<i>PARP6</i>	GA	GG	GG	GA	GA	GA	GG	GA
<i>KTN1</i>	CT	CC	CT	CT	CT	CC	CT	CT
<i>NEXN</i>	AG	AA	AG	AG	AG	AA	AG	AG
<i>PCNX</i>	CT	CC	CC	CT	CT	CC	CT	CT
<i>PTPRF</i>	AG	AA	AG	AG	AA	AG	AG	AA

497 Exome sequencing was performed on genomic DNA of two family members. Segregation of the identified variants in family members was
498 investigated by the use of Sanger sequencing. The variants that were identified with exome sequencing in *DCAF8* and *GTPBP2* could not be
499 confirmed by Sanger sequencing in the family members. Therefore, Sanger sequencing for these variants in the rest of the family members
500 was not performed. Family members that were diagnosed with diabetes (affected) are indicated in grey.

501 **Table 4.** Predicted interaction partners for *PTPRF* and *ASXL1*.

<i>PTPRF</i>		
Gene symbol	Gene name and function	Confidence score
<i>PPFIA1</i>	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1. Binds to the intracellular membrane-distal phosphatase domain of PTPRF. This interaction may regulate the disassembly of focal adhesion and thus help orchestrate cell-matrix interactions.	0.950
<i>INSR</i>	Insulin receptor. Binding of insulin to this receptor stimulates glucose uptake. Inhibiting/disrupting of insulin binding to <i>INSR</i> results in insulin resistance and T2DM. Polymorphisms within this gene are associated with insulin resistance and T2DM.	0.913
<i>LRFN4</i>	Leucine rich repeat and fibronectin type III domain containing 4; Promotes neurite outgrowth in hippocampal neurons	0.910
<i>CTNNB1</i>	Catenin (cadherin-associated protein), beta 1. The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells	0.889
<i>IRS1</i>	Insulin receptor substrate 1. Located downstream of <i>INSR</i> in the insulin signaling pathway. Insulin activates <i>INSR</i> , which phosphorylates and recruits different substrate adaptors such as the IRS family of proteins. Mutations in <i>IRS</i> genes are associated with T2DM and susceptibility to insulin resistance.	0.884
<i>IRS2</i>	Insulin receptor substrate 2. Located downstream of <i>INSR</i> in the insulin signaling pathway. Insulin activates <i>INSR</i> , which phosphorylates and recruits different substrate adaptors such as the IRS family of proteins. Mutations in <i>IRS</i> genes are associated with T2DM and susceptibility to insulin resistance.	0.876
<i>MAPK1</i>	Mitogen-activated protein kinase 1; Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements.	0.857
<i>PTPN1</i>	Protein tyrosine phosphatase, non-receptor type 1; Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response	0.838
<i>LRRC4B</i>	Leucine rich repeat containing 4B; Synaptic adhesion protein. Regulates the formation of excitatory synapses	0.831
<i>PARL</i>	Presenilin associated, rhomboid-like; Required for the control of apoptosis during postnatal growth	0.829
<i>ASXL1</i>		
<i>BAP1</i>	BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase); Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Acts as a regulator of cell growth.	0.980
<i>EZH2</i>	Enhancer of zeste 2 polycomb repressive complex 2 subunit. Family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein may play a role in the hematopoietic and central nervous systems	0.979
<i>HCFC1</i>	Host cell factor C1 (VP16-accessory protein); Involved in control of the cell cycle. Regulation of transcription	0.956

<i>SUZ12</i>	SUZ12, polycomb repressive complex 2 subunit. This zinc finger gene has been identified at the breakpoints of a recurrent chromosomal translocation reported in endometrial stromal sarcoma.	0.952
<i>UBC</i>	ubiquitin C. The encoded protein is a polyubiquitin precursor. Conjugation of ubiquitin monomers or polymers can lead to various effects within a cell, depending on the residues to which ubiquitin is conjugated. Ubiquitination has been associated with protein degradation, DNA repair, cell cycle regulation, kinase modification, endocytosis, and regulation of other cell signaling pathways	0.946
<i>FOXK2</i>	Forkhead box K2; Recognizes the core sequence 5'-TAAACA-3'. Binds to NFAT-like motifs (purine-rich) in the IL2 promoter. May be involved in both positive and negative regulation of important viral and cellular promoter elements	0.942
<i>FOXK1</i>	Forkhead box K1; Transcriptional regulator that binds to the upstream enhancer region (CCAC box) of myoglobin gene. Has a role in myogenic differentiation and in remodeling processes of adult muscles that occur in response to physiological stimuli.	0.940
<i>OGT</i>	O-linked N-acetylglucosamine (GlcNAc) transferase; Catalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in cytoplasmic and nuclear proteins.	0.938
<i>EZH1</i>	Enhancer of zeste 1 polycomb repressive complex 2 subunit. EZH1 is a component of a noncanonical Polycomb repressive complex-2 (PRC2) that mediates methylation of histone H3 lys27 (H3K27) and functions in the maintenance of embryonic stem cell pluripotency and plasticity	0.935
<i>EED</i>	embryonic ectoderm development. This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein mediates repression of gene activity through histone deacetylation, and may act as a specific regulator of integrin function	0.934

Figure 1. Protein-protein interaction (PPI) networks of *PTPRF* and *ASXL1*

514 **Figure legends**

515

516 **Figure 1.** Protein-protein interaction (PPI) networks of *PTPRF* and *ASXL1*.

517 PPI networks of **(A)** *PTPRF* and **(B)** *ASXL1*. A confidence score is assigned to each
518 interaction based upon direct (physical) and indirect (functional) associations.

519 Confidence score cut-off was $\geq 0,7$ (high confidence)

520

521